Anthera Pharmaceuticals, Inc. (NASDAQGM:ANTH) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $0.67, up from yesterday’s close by -0.74%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
This company has been competing with others in the space and offers its own combination of interesting factors Anthera Pharmaceuticals, Inc. (ANTH) currently trades with a market capitalization of $28.19M.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ANTH, the company currently has $32.57M of cash on the books, which is offset by $0.00 current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $-24.92M over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of -0.41 on a per share basis this quarter. Perhaps, that suggests something about why 44.50% of the outstanding share supply is held by institutional investors.
No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Anthera Pharmaceuticals, Inc. recorded a 52-week high of 4.90. It is now trading 4.22 off that level. The stock is trading 1.43 its 50-day moving average by 0.75. The stock carved out a 52-week low down at 0.64.
In recent action, Anthera Pharmaceuticals, Inc. (ANTH) has made a move of -62.15% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 101.53, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 36.81M with 12.83% sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ANTH.